SBRT + TACE for Primary Hepatocellular Carcinoma
NCT00746655
Withdrawn
The purpose of this study is to determine the feasibility and toxicity of combining SBRT and TACE for unresectable HCC and to evaluate the Health Related Quality of Life (HRQL) associated with combined therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/23/2015
Locations: UPMC Presbyterian/Montifore, Pittsburgh, Pennsylvania +3 locations
Conditions: Hepatocellular Carcinoma
Register for Updates
Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT
NCT00084838
Completed
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Giving more than one chemotherapy drug with radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving intrathecal and systemic combination chemotherapy together with radiation therapy works in treating young patients with newly diagnosed central nervous system (CNS)... Read More
Gender:
ALL
Ages:
18 years and below
Trial Updated:
12/18/2015
Locations: Stanford Cancer Center, Stanford, California +11 locations
Conditions: Central Nervous System Tumor, Pediatric
Register for Updates
Multimodality Treatment for Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) - BEACON Study: Bevacizumab and Chemotherapy for Operable NSCLC
NCT00130780
Completed
This is a phase II, single institution trial for patients with clinical Stage IB-IIIA NSCLC (T1-3N0-2M0) who have resectable lung tumors. The primary goal of this study is to show that the addition of bevacizumab to a cisplatin-based chemotherapy in the neoadjuvant setting for non-squamous cell carcinomas improves the rate of pathologic downstaging, which correlates with survival. Downstaging is defined as any decrease in the final pathologic stage compared with the clinical stage before inducti... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/18/2015
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Phase II Trial of Preoperative Combined Modality Therapy for Esophageal Carcinoma: Cisplatin-Irinotecan Followed by Radiation Therapy With Concurrent Cisplatin and Irinotecan.
NCT00590031
Completed
Patients with surgically resectable T1N1M0 or T2-4N any M0 esophageal carcinoma will receive six weeks of induction chemotherapy with weekly irinotecan and cisplatin given weeks 1, 2, 4 and 5. Patients will then receive weekly irinotecan, cisplatin, and concurrent radiotherapy with chemotherapy given once weekly, weeks 8,9,11 and 12 during the six weeks of radiotherapy. Patients will be referred for surgery 4-8 weeks after completion of chemoradiotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/18/2015
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Esophageal Carcinoma
Register for Updates
Phase II Study of Chemotherapy and Pamidronate for the Treatment of Newly Diagnosed Osteosarcoma
NCT00586846
Completed
This study is designed to test the safety and feasibility of the simultaneous administration of a biphosphonate with chemotherapy for the treatment of osteosarcoma in newly diagnosed patients.
Gender:
ALL
Ages:
All
Trial Updated:
12/15/2015
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Osteosarcoma
Register for Updates
Intravenous and Intraperitoneal Paclitaxel, Intraperitoneal Cisplatin, and Intravenous Bevacizumab for the Initial Treatment of Optimal Stage II or III Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
NCT00588237
Completed
The purpose of this study is to test whether it is safe to treat your cancer with 3 drugs instead of 2 drugs. After surgery, your cancer is typically treated with 2 drugs called cisplatin and paclitaxel (also known as Taxol). Cisplatin is given through a port in your belly, and Taxol is given both through the belly port and through the vein (IV). Large clinical studies have shown that this treatment gives the best results for women with your cancer. This treatment, however, also causes many side... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/15/2015
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Ovarian Cancer, Primary PERITONEUM, Fallopian Tube Cancer
Register for Updates
A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer
NCT01304784
Completed
This study is an open-label, dose-escalation study of MM-111 with five different combination treatments with the main goal of determining the safety of MM-111 with each combination.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/15/2015
Locations: Rocky Mountain Cancer Centers, Denver, Colorado +14 locations
Conditions: HER-2 Gene Amplification
Register for Updates
Chemoradiotherapy With Elective Low Dose Nodal Radiation for Locally Advanced Head and Neck Cancer
NCT01372111
Unknown
Concurrent chemotherapy and radiation therapy (chemoRT) has become the standard of care for treatment of many patients with advanced head and neck squamous cell carcinoma (HNSCC), though many clinical questions remain. Prior experience has revealed locoregional control (LRC), disease free survival (DFS) and overall survival (OS) at 3 years exceeding 80% after treatment with the use of hyperfractionated intensity modulated radiation therapy (IMRT) and concurrent weekly cisplatin chemotherapy for... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/08/2015
Locations: Coleman Radiation Oncology Center, Morehead City, North Carolina +4 locations
Conditions: Head and Neck Cancer
Register for Updates
Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer
NCT00702299
Completed
RATIONALE: Pemetrexed may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving pemetrexed together with cisplatin and paclitaxel and giving them in different ways may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of intraperito... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/02/2015
Locations: Arizona Oncology - Scottsdale, Scottsdale, Arizona +1 locations
Conditions: Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Register for Updates
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
NCT00003273
Withdrawn
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of different regimens of combination chemotherapy followed by peripheral stem cell transplantation in treating children who have newly diagnosed brain tumor.
Gender:
ALL
Ages:
10 years and below
Trial Updated:
11/30/2015
Locations: Cancer Research Center of Hawaii, Honolulu, Hawaii +18 locations
Conditions: Brain and Central Nervous System Tumors, Neuroblastoma, Retinoblastoma, Sarcoma
Register for Updates
Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer
NCT01109524
Completed
The purpose of the study is to determine if U.S. manufactured Cetuximab can be safely used for the treatment of Non-Small Cell Lung Cancer in combination with Cisplatin and Vinorelbine.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/24/2015
Locations: Donald W. Hill M.D., P.C., Casa Grande, Arizona +21 locations
Conditions: Lung Neoplasms, Carcinoma, Cancer of the Lung, Non-Small-Cell Lung Carcinoma
Register for Updates
S0414 Cetuximab, Combo Chemo, and RT in Locally Advanced Esophageal Cancer
NCT00109850
Terminated
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Cetuximab may also stop the growth of esophageal cancer by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin and irinotecan, work in different ways to stop the growth of tu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/16/2015
Locations: Mobile Infirmary Medical Center, Mobile, Alabama +131 locations
Conditions: Esophageal Cancer
Register for Updates